Healthcare in India

Plainsight Delivers Enterprise Vision AI on Google Cloud Marketplace

Retrieved on: 
Monday, July 26, 2021

SAN FRANCISCO, July 26, 2021 /PRNewswire-PRWeb/ -- Plainsight, the leader in proven vision AI, today announced its availability on Google Cloud Marketplace, providing Google Cloud customers with easy deployment of its end-to-end vision AI platform.

Key Points: 
  • SAN FRANCISCO, July 26, 2021 /PRNewswire-PRWeb/ -- Plainsight, the leader in proven vision AI, today announced its availability on Google Cloud Marketplace, providing Google Cloud customers with easy deployment of its end-to-end vision AI platform.
  • Google Cloud Marketplace is a procurement and fulfillment platform where enterprises can find, deploy, and manage production-ready solutions built by partners, open-source projects, and Google Cloud.
  • Solutions are vetted by Google Cloud and optimized to run on Google Cloud Marketplace to simplify configuration and speed up deployment times.
  • With Google Cloud Marketplace deployment into their private networks, enterprises can equip teams across business units with the power of Plainsight vision AI to enable them to:
    Easily access powerful vision AI tools leveraging Google Cloud resources for global scale, increased security, bolstered privacy, unified billing, and cost savings
    Continuously train high-accuracy vision AI models with an intuitive, no-code interface
    "Plainsight is excited about the expansion of our partnership with Google Cloud that makes our vision AI platform even more accessible to innovative enterprises," said Carlos Anchia, CEO of Plainsight.

Intersec Worldwide, a global leader in digital forensics, incident response and risk management, has been named to Enterprise Security Magazine's Top 10 Digital Forensics Services Companies of 2021

Retrieved on: 
Monday, July 26, 2021

NEWPORT BEACH, Calif., July 26, 2021 /PRNewswire/ -- "We are excited to have been named one of Enterprise Security Magazine's Top 10 Digital Forensics Companies for 2021 and to have a featured cover page article," said Jeff Tutton, President, Intersec Worldwide.

Key Points: 
  • NEWPORT BEACH, Calif., July 26, 2021 /PRNewswire/ -- "We are excited to have been named one of Enterprise Security Magazine's Top 10 Digital Forensics Companies for 2021 and to have a featured cover page article," said Jeff Tutton, President, Intersec Worldwide.
  • Intersec Worldwide experts conduct a wide variety of forensic investigations that encompass a variety of enterprise environments.
  • From this we have been fortunate enough to work on some of the largest digital forensics and incident response events in the world, throughout multiple industries, including financial services, e-commerce, healthcare, energy and retail.
  • The Global Digital Forensics Market segments and Market Data Breakdown are detailed below:Type (Hardware, Software, Services), Application (Computers, Laptops, Smartphones, Thumb Drives, External Hardware Drives), Services (Computer Forensics, Network Forensics, Mobile Devices Forensics, Digital Image Forensics, Digital Video/Audio Forensics, Memory Forensics)
    Regions Covered in the Digital Forensics Market:

Healthcare Revenue Cycle Management Market Revenue 2021: Top 6 Vital Trends Influencing the Industry Growth Curve Through 2027: Global Market Insights Inc.

Retrieved on: 
Monday, July 26, 2021

Healthcare revenue cycle management solutions are increasingly deployed to increase efficiency and profitability.

Key Points: 
  • Healthcare revenue cycle management solutions are increasingly deployed to increase efficiency and profitability.
  • However, the consistent changes in numerous healthcare regulatory compliances could restrain the overall market demand to some extent.
  • Asia Pacific healthcare revenue cycle management market accounted for more than 14.5% of revenue share in 2020.
  • The higher availability of health insurance across North America is another impact-rendering factor for the healthcare revenue cycle management market progression.

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results

Retrieved on: 
Tuesday, July 13, 2021

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the fiscal year ended April 30, 2021.

Key Points: 
  • KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the fiscal year ended April 30, 2021.
  • No revenue was recognized for the fiscal year ended April 30, 2021, compared to $12.7 million for the prior fiscal year.
  • Research and development expenses were $41.3 million for the fiscal year ended April 30, 2021, compared to $40.2 million for the prior fiscal year.
  • On July 11, 2021, the Board of Directors adopted the KalVista Pharmaceuticals, Inc. 2021 Inducement Equity Incentive Plan (the Plan).

FFF Enterprises Celebrates 33 Years of Helping Healthcare Care®

Retrieved on: 
Thursday, July 8, 2021

FFF Enterprises business models and innovations continue to evolve to ensure the safety and efficacy of the biopharmaceuticals marketplace.

Key Points: 
  • FFF Enterprises business models and innovations continue to evolve to ensure the safety and efficacy of the biopharmaceuticals marketplace.
  • With more than 33 years of experience in product allocation management, FFF Enterprises is dedicated to meeting the needs of our most precious patients.
  • Everything we do affirms our dedication to sustain a reliable, secure pharmaceutical supply chain in the pursuit of our mission of Helping Healthcare Care.
  • Please visit FFF Enterprises' news site , as well as LinkedIn , Instagram , Facebook and YouTube for more information about the company.

Hardware Security Modules Market worth $1.8 billion by 2026 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, July 6, 2021

It is mandatory for pharmaceuticals companies developing new medicines to follow the standards of security and privacy.

Key Points: 
  • It is mandatory for pharmaceuticals companies developing new medicines to follow the standards of security and privacy.
  • Cloud signing solutions help pharmaceuticals companies save substantially on shipping charges and accelerate time to market and development of new drugs.
  • The European market for hardware security modules has been segmented into Germany, the UK, France, Italy, the Netherlands, and the Rest of Europe.
  • Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model GEM".

Hardware Security Modules Market worth $1.8 billion by 2026 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, July 6, 2021

It is mandatory for pharmaceuticals companies developing new medicines to follow the standards of security and privacy.

Key Points: 
  • It is mandatory for pharmaceuticals companies developing new medicines to follow the standards of security and privacy.
  • Cloud signing solutions help pharmaceuticals companies save substantially on shipping charges and accelerate time to market and development of new drugs.
  • The European market for hardware security modules has been segmented into Germany, the UK, France, Italy, the Netherlands, and the Rest of Europe.
  • Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model GEM".

Hyloris Successfully Renegotiates License Agreements for Lead Products with the Alter Pharma Group

Retrieved on: 
Thursday, June 24, 2021

Hyloris will pay the Alter Pharma Group a total lump sum of 5.25 million plus 0.5 million potential earn-out, thereby waiving any further future financial obligations towards the Alter Pharma Group.

Key Points: 
  • Hyloris will pay the Alter Pharma Group a total lump sum of 5.25 million plus 0.5 million potential earn-out, thereby waiving any further future financial obligations towards the Alter Pharma Group.
  • Hyloris Pharmaceuticals and the Alter Pharma Group have amended and unwound the earlier license agreements as follows:
    The patent and knowhow license agreement in relation to Maxigesic IV has been altered to forego all past commitments and all further future royalty obligations to the Alter Pharma Group in relation to Maxigesic IV.
  • The renegotiated and unwound agreements announced today are related to the arrangements outlined below that Hyloris Pharmaceuticals had with the subsidiaries of the Alter Pharma Group, including Generic Specialty Pharma, Nordic Specialty Pharma, Stasisport Pharma and Neogen Developments.
  • Under the various transactional agreements between Hyloris and the subsidiaries of the Alter Pharma Group, Hyloris was required to pay these entities a combination of licensing fees, milestone payments and royalty payments.

Worldwide Managed Equipment Services & Enterprise Compliance and Quality Management Industry to 2029 - Key Market Trends and Future Outlook

Retrieved on: 
Wednesday, June 16, 2021

DUBLIN, June 16, 2021 /PRNewswire/ -- The "Managed Equipment Services (MES) & Enterprise Compliance and Quality Management (ECQM) Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, June 16, 2021 /PRNewswire/ -- The "Managed Equipment Services (MES) & Enterprise Compliance and Quality Management (ECQM) Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com's offering.
  • Managed Equipment Services (MES) and Enterprise Compliance and Quality Management (ECQM) refer to solutions used to streamline the huge volumes of data in organizations.
  • The MES & ECQM market is strongly supported by the rising demand for medical devices, pharmaceuticals and research amongst these industries.
  • The report titled "Global MES & ECQM Market- Growth, Share, Opportunities and Competitive Analysis, 2021 - 2029" offers strategic insights into the global MES & ECQM market along with the market size and estimates for the duration 2019 to 2029.

Aucta Pharma and Oakrum Pharma Announce Launch of Generic Version of JADENU(R) Sprinkle (Deferasirox Granules)

Retrieved on: 
Monday, June 14, 2021

PISCATAWAY, N.J., June 14, 2021 /PRNewswire/ -- Aucta Pharmaceuticals, Inc. (Aucta) has partnered with Oakrum Pharma, out of St. Louis, Missouri, to announce the U.S. launch of a generic version of JADENU Sprinkle (Deferasirox Granules) in 90mg, 180mg, and 360mg strengths.

Key Points: 
  • PISCATAWAY, N.J., June 14, 2021 /PRNewswire/ -- Aucta Pharmaceuticals, Inc. (Aucta) has partnered with Oakrum Pharma, out of St. Louis, Missouri, to announce the U.S. launch of a generic version of JADENU Sprinkle (Deferasirox Granules) in 90mg, 180mg, and 360mg strengths.
  • Shoufeng Li, CEO of Aucta Pharmaceuticals stated, "We are excited to bring another Aucta Pharmaceuticals developed product to the U.S. market through this partnership with Oakrum Pharma.
  • Aucta Pharmaceuticals, Inc. is a research and technology based pharmaceutical company focusing on the development and commercialization of niche generic and branded specialty products.
  • Oakrum Pharma, LLC is a privately-owned biopharmaceutical company focusing on development and commercialization of affordable drug therapies.For more information, visit www.oakrumpharma.com .